Dose adjusted‐EPOCH‐R and mediastinal disease may improve outcomes for patients with gray‐zone lymphoma. (5th July 2016) - Chihara, Dai; Westin, Jason R.; Miranda, Roberto N.; Cheah, Chan Y.; Oki, Yasuhiro; Turturro, Francesco; Romaguera, Jorge E.; Neelapu, Sattva S.; Nastoupil, Lorreta J.; Fayad, Luis E.; Rodriguez, M. Alma; Fowler, Nathan H.; et al.